Feasibility study of new calibrators for thyroid stimulating hormone (TSH) immunoprocedures based on remodeling of recombinant TSH to mimic glycoforms circulating in patients with thyroid disorders.
It has been widely assumed that antibodies recognize peptidic determinants of TSH with virtually no effect from changes in glycosylation; however, earlier studies indicated that the presence or absence of specific glycans modified the immunoreactivity of TSH, particularly when these changes occurred in the [beta]-subunit (28-30). Furthermore, pituitary and recombinant forms of TSH origin usually share high cross-reactivity but clearly do not behave identically (5,31). More recently, our laboratory has shown that monoclonal anti-TSH antibodies can be divided into 2 groups depending on their capacity to bind TSH forms with altered glycosylation (32). Indeed, some antibodies were unable to bind sialylated forms of TSH, whereas others failed to detect nonfucosylated TSH (32). Because both alterations are known to occur in patients developing common thyroid disorders, particularly hypothyroidism (10-14), it may be that some antibodies fail to detect disease-related TSH glycoforms, particularly during the onset of hypothyroidism.
Measurement of TSH as an indicator of thyroid function has become one of the most popular tests in laboratory medicine (33), but inter- and intralaboratory variations in TSH measurements have been observed over the past 20 years (34-43). Assays routinely measure a nondetermined, highly heterogeneous mixture of glycoforms and possibly degradation products of TSH against a Reference Material consisting of a quite distinct combination of glycoforms composed of immature and mature biosynthetic intermediates (44). Both preparations may eventually share common glycoforms, but they should not be assumed to behave identically (45). Ideally, the best candidate for a Reference Material should display the same epitope distribution as TSH circulating in healthy individuals and in patients with thyroid disorders. However, there are indications (10-14) that the circulating forms of TSH differ between euthyroid and hypothyroid persons. In this study, we aimed to identify the sources of variation in TSH measurements and designed a feasibility study to develop TSH preparations that resemble as closely as possible the wide array of serum forms of TSH.
TSH circulates in such low amounts that measurement of the protein concentration and/or structural characterization of the glycan structure are not possible. We have attempted immunopurification of TSH, but although the antibodies bound biantennary TSH forms, they failed to isolate the whole array of glycoforms suspected to circulate in patients. To overcome these technical limitations, we used a recombinant preparation of TSH with well-established polypeptide and glycan structures [(32) and Morelle et al., "Site-Specific Glycosylation of Recombinant Human Thyrotropin," manuscript in preparation] that contained many of the glycoforms considered to be present in serum. We produced a panel of recTSH preparations differing in glycosylation patterns (Scheme 2). To properly assess the similarities in epitope distribution, we used pairs of antibodies mapping 3 remote antigenic clusters of the TSH molecule as present in each of the candidate preparations. To our knowledge, this is the first report of a method that enables estimation of epitope distribution on a molar basis and can be used to produce new candidate reference materials for further standardization of TSH measurements as recommended by European Directive DIV 98/79/CE.
Materials and Methods
The monoclonal antibodies were a generous gift from Ortho-Clinical Diagnostics (Issy-Les-Moulineaux, France), Roche Diagnostics (Basel, Switzerland), and Bayer Diagnostics (Puteaux, France) or were purchased from Beckman-Coulter and Seradyn. The 2nd International Reference Preparation (IRP) for pitTSH (80/558) and the 1st IRP for recTSH (94/674) were from the National Institute for Biological Standards and Control (NIBSC, United Kingdom). Highly purified human pitTSH was from Biogenesis, and recombinant human TSH was from Seradyn.
Neuraminidase, bovine serum albumin (BSA), a-methylmannopyranoside, cacodylic acid, Triton X-100, CMPN-acetylneuraminic acid, p-nitrophenyl phosphate, and Tween 20 were from Sigma. All culture reagents were from Invitrogen-Life Technologies. The streptavidin-alkaline phosphatase conjugate was from Jackson ImmunoResearch Laboratories, the Micro BCA[TM] Protein Assay was from Pierce-PERBIO, the biotin labeling reagents were from Roche, lentil lectin-Sepharose was from AmershamPharmacia Biotech, and the chromatography columns and microtiter 96-well plates were from VWR International.
Serum samples (0.2-1.5 mL) were collected from patients with overt primary hypothyroidism [TSH >50 mIU/L and free thyroxine <8 pmol/L] and from patients without thyroid glands, which had been removed years previously because of thyroid cancer. In these patients, the TSH-suppressive thyroxine therapy was stopped for ~2 months. Only sera with TSH concentrations >50 mIU/L and low free thyroxine (<5 pmol/L) were included in the collection. All samples were collected anonymously and stored at -20 [degrees]C. The measurements were performed on the ADVIA Centaur (Bayer). For this study, sera from 63 patients with TSH concentrations ranging from 60 to 150 mIU/L were used.
To enable conversions of serum TSH values provided to us as mIU/L into molar protein content (ng/L protein), we first established an in-house conversion factor by comparing a highly purified commercially available pitTSH to the 2nd human pitTSH (IRP 80/558; NIBSC). We checked the homogeneity of the highly purified pitTSH by sodium dodecyl sulfate-gel electrophoresis (data not shown) and by mass spectrometry (32). An epitope map of both preparations was made under saturating conditions at equilibrium to control for epitope identity (data not shown). Dose-response curves were constructed with used of aliquots of the highly purified preparation quantified by an ultrasensitive protein assay as described below. In this way, we confirmed that the appropriate conversion factor was 4.93 mN/[micro]g, very similar to that mentioned in the datasheet for the NIBSC 80/558 standard. Under these conditions, a serum TSH titer of 98.6 mIU/L was assigned the value 2 ng/100 [micro]L.
We determined the protein concentrations of all TSH preparations after modifying the experimental procedure for the protein assay by selecting recTSH as the in-house calibrator for protein determination. Protein content was determined by absorbance and amino acid composition to establish the molar content, irrespective of the carbohydrate composition. This value was then used throughout all subsequent determinations, which were carried out as recommended by the manufacturer. Briefly, 1 mL of recTSH internal standard or unknown sample was mixed with 1 mL of the working reagent provided with the assay and incubated in a 60 [degrees]C water bath for 1 h. After all of the tubes had cooled to room temperature, the absorbance at 562 nm was measured.
PRODUCTION OF AN ENGINEERED [alpha]2,6-SIALYLTRANSFERASE
To produce a soluble recombinant [alpha]2,6-sialyltransferase, we established a stable CHO cell line that produced [beta]-galactoside [alpha]2,6-sialyltransferase (CHO-K1/hST6Ga1 I) (46). The cells were grown at 37 [degrees]C in a 5% C[O.sub.2] incubator, in DMEM-Glutamax-I medium supplemented with 100 mL/L inactivated fetal calf serum, fungizone (2.5 mg/L), gentamicin (50 mg/L), and geneticin (200 mg/L). The cell culture medium was collected after a 72-h period and concentrated ~15-fold by centrifugation with Amicon Centriprep units (Millipore). Batches were pooled, and the soluble enzymatic activity was determined as described previously (46). Under these conditions, the enzyme activity was estimated to be 60-100 U/L, and aliquots were stored at -20 [degrees]C.
REMODELING OF recTSH SIALIC ACID CONTENT
The enzymatic treatments of recTSH preparations are summarized in the 4 larger panels in Scheme 2.
Desialylated recTSH (OSial-recTSH) was obtained by incubating recTSH with neuraminidase (enzyme activity, 20 mU/[micro]g of protein) from Clostridium perfringens for 2 h at 37 [degrees]C, under gentle stirring in 100 mmol/L sodium acetate (pH 6.5) containing 2 mmol/L Ca[Cl.sup.2] and 0.3 g/L BSA.
Oversialylatedf recTSH (3/6Sial-recTSH) was prepared by incubating recTSH for 2 h at 37 [degrees]C with in-house hST6Ga1 I enzyme (enzyme activity, 20 mU/[alpha] of TSH) in the presence of 15 mmol/L CMP-N-acetylneuraminic acid, 2 mmol/L Mn[Cl.sup.2], 1 g/L BSA, and 10 mL/L Triton X-100 in 50 mmol/L cacodylate buffer (pH 6.5).
Resialylated recTSH (6Sial-recTSH) was obtained by neuraminidase-agarose treatment (enzyme activity, 20 mU/[micro]g of protein) in 50 mmol/L acetate (pH 6.5). The insoluble enzyme was removed by centrifugation at 7508 for 1 min. Asialo-TSH was incubated with h5T6Ga1 I as mentioned for 3/6Sial-recTSH.
The protein concentrations of all of the preparations were determined by protein assay as described above.
AFFINITY CHROMATOGRAPHY ON LENTIL LECTIN-SEPHAROSE
The fractionation of sialylated recTSH preparations is summarized in the 4 smaller panels at the bottom of Scheme 2.
Lentil lectin-Sepharose (1 mL) was equilibrated with 10 mL of buffer containing 10 mmol/L Tris-HCl (pH 8.0),150 mmol/L NaCl, 1 mmol/L Mg[Cl.sub.2], 1 mmol/L Mn[Cl.sub.2], and 1 mmol/L Ca[Cl.sub.2] We chose to use fractionation of remodeled recTSH (20 fig) on the lectin column as representative of ~1 L of serum with highly increased TSH. After incubation for 2.5 h at room temperature to facilitate interaction, the sample was packed into a 3-mL column. Unbound TSH was collected by centrifugation 10 times with 1 mL of buffer (buffer removed after every centrifugation and new buffer added). The bound fraction was collected by the same procedure and the same buffer supplemented with 500 mmol/L [alpha]-methylmannopyranoside (32). Finally, we determined the TSH content by testing the various fractions in an in-house ELISA, using the initial appropriate sialylated preparation with known molar content as the calibrator.
A panel of 10 monoclonal antibodies was characterized recently (32) and was used throughout the study. All experiments were carried out at equilibrium. Microtiter plates were coated with monoclonal anti-TSH antibodies (1 [micro]g) in 100 [micro]L of 50 mmol/L PBS (pH 7.5) for 2 h at 37 [degrees]C. After each step, the wells were washed with PBS containing 0.5 mL/L Tween 20. The wells were then incubated with 20 g/L BSA in PBS to saturate the nonspecific binding sites. Portions (containing 2 ng of TSH, the half-maximal concentration of all assays) of the various preparations, lectin fractions, or serum samples were added to the wells and incubated overnight at 4 [degrees]C in PBS containing 1 g/L BSA. This buffer was used because the same binding was observed when recTSH was incubated in the presence of rabbit nonimmune serum or human hyperthyroid serum (data not shown). Bound TSH forms were detected by incubation for 2 h at 37 [degrees]C with 100 ng of 4 different biotinylated anti-TSH monoclonal antibodies. Visualization was with the streptavidin-alkaline phosphatase conjugate (100 ng) and p-nitrophenyl phosphate substrate (100 [micro]g). All assays were performed in duplicate, and the data are reported as a mean of these values.
Under these conditions, the panel of our preparations could be similarly calibrated with the 2nd IRP for pitTSH (80/558) and the 1st IRP for recTSH (94/674) despite a maximal binding capacity that varied by as much as 100% (47) (see Figs. 51 and 52 in the Data Supplement that accompanies the online version of this article at http: //www.clinchem.org/content/vol52/issue2/).
Very recent work from our laboratory has shown that changes in TSH glycosylation alter the expression of several epitopes (32) in the TSH molecule. Accordingly, we proposed that discordance among routine measurements of serum TSH originated from both the determinants targeted by the assays and the pitTSH calibrator, which does not display the same epitope pattern as serum TSH. In this study, we aimed at defining the feasibility of harmonizing TSH assays by use of new calibrators independent of the current IRPs. For this purpose, we estimated the epitope patterns of novel TSH preparations on a molar basis.
We used a panel of 23 assays to map 3 remote areas in the TSH molecule that were common to pituitary and recombinant TSH (32) (see Fig. 53 in the online Data Supplement). To identify the best mimic of serum TSH, we used samples from patients with highly increased TSH because they represent conditions in which the circulating hormone is present in nanograms per 100 [micro]L of serum and can be quantitatively compared with the calibrators. Because the glycosylation pattern of TSH was found to significantly alter the expression of all 3 antigenic clusters, we designed a series of recTSH preparations with modified terminal and/or internal glycosylation and compared their respective epitope distributions before screening them against serum samples. Unfortunately, the TSH concentrations of euthyroid patients as well as patients with subclinical hypothyroidism are far too low to be measured in the current analysis.
COMPARATIVE ANALYSIS of pitTSH, recTSH, AND SERUM TSH
As shown in Fig. 1A, the highly purified recombinant preparation (y) was poorly correlated with pitTSH (x) when tested at half-maximal concentrations and at equilibrium. We obtained a mean (SD) slope for the linear regression of 1.769 (0.055), which indicated that the monoclonal antibodies preferentially bound the recombinant preparation, as described recently (32). When pitTSH (x) was compared with serum TSH (y) from patients with TSH concentrations >60 mN/L (Fig. 1B), the slope was 2.124 (0.001), indicating that the pituitary preparation also poorly resembled the circulating hormone. On the other hand, recTSH (x) and serum TSH (y) immunoreacted very similarly, although not identically (Fig. 1C), with a slope of 1.178 (0.056). These observations support the notion that the recombinant compound better mimicked circulating long-lived TSH glycoforms because it displays a more closely related glycosylation pattern (see Scheme 1).
[FIGURE 1 OMITTED]
To identify which TSH preparations) best fits) the circulating hormone, we engineered various recTSH forms with variable terminal and/or internal glycosylation and compared their epitope expression with that of the recTSH.
COMPARISON BETWEEN reCTSH AND ENZYMATICALLY REMODELED reCTSH PREPARATIONS
Although circulating TSH has been shown to have higher sialic acid content than does pitTSH (12,13), the nature of the glycosidic linkages) has not been determined in the native or serum hormone. We therefore enzymatically remodeled the terminal sialylation of the recombinant hormone according to [alpha]2,3- and/or [alpha]2,6-linkages. Because CHO cells have been found to specifically sialylate glycans in the [alpha]2,3 position (4-7), we used an [alpha]2,6-sialyltransferase produced in the laboratory (46) to introduce this alternative [alpha]2,6-sialylation. As summarized in Scheme 2, recTSH was treated with neuraminidase to remove sialic acid and produce OSial-recTSH or was reacted with [alpha]2,6-linked sialic acid to produce 3/6SialrecTSH. In addition, desialylated TSH was enzymatically resialylated to produce a preparation designated 6SialrecTSH, which contained [alpha]2,6-sialic acid exclusively. Accordingly, the slopes for the linear regression between the remodeled recTSH forms (y) and recTSH (x) were 0.860 (0.057) for OSial-recTSH (Fig. 2A), 1.090 (0.084) for 3/6Sial-recTSH (Fig. 2B), and 1.227 (0.029) for 6SialrecTSH (Fig. 2C). These results indicated that oversialylated and resialylated recTSH forms (Fig. 2, B and C) are good candidates to mimic hormone sialylation as may occur in serum, at least after the onset of hypothyroidism (10-13). We then concentrated our efforts on further refining these 2 preparations and adding a second level of heterogeneity, namely core fucosylation.
COMPARISON BETWEEN OVERSIALYLATED AND RESIALYLATED reCTSH AND reCTSH AS A FUNCTION OF CORE FUCOSYLATION
Because core fucosylation has been reported to decrease in circulating TSH as hypothyroidism develops (14), we were interested in comparing the epitope distribution of TSH preparations varying in both terminal and inner glycosylation. Fractionation of remodeled preparations by lentil lectin chromatography yielded an unbound fraction that contained exclusively nonfucosylated TSH glycoforms and a bound fraction that contained TSH glycoforms with at least 1 fucosylated glycan at either 1 of the 3 N-glycosylation sites.
The nonfucosylated, oversialylated recTSH, designated 3/6Sial(-Fuc)-recTSH (Scheme 2), displayed slightly decreased binding compared with 3/6Sial-recTSH (Fig. 3A), giving in a slope of 1.046 (0.090), whereas the fucosylated fraction [3/6Sial(+Fuc)-recTSH; Fig. 3B] was not significantly affected, as shown by the slope of 1.095 (0.075). These findings revealed that alteration in fucose content did not affect the estimation of 3/6Sial-recTSH. The results were similar when we used the 6Sial-recTSH preparation; the slopes were 0.840 (0.017) and 0.976 (0.024) for the nonfucosylated [6Sial(-Fuc)-recTSH] and fucosylated [6Sial(+Fuc)-recTSH] fractions, respectively (Fig. 3, C and D). However, we noted that measurements became highly dispersed, indicating that antibody recognition was significantly affected when TSH lacked fucose (see also below).
[FIGURE 2 OMITTED]
COMPARISON BETWEEN REMODELED PREPARATIONS AND SERUM TSH
We then compared all preparations with a pool of sera from patients with increased TSH (Fig. 4). Basically, the slope varied widely, indicating that the TSH glycosylation pattern rather strongly alters the quantitative epitope expression and, consequently, the performances of the various assays.
Slopes varied between 1.064 (0.057) for 3/6Sial-recTSH (Fig. 4A) and 0.953 (0.033) for 6Sial- recTSH (Fig. 4B) compared with 1.178 (0.056) for the initial 3Sial-recTSH preparation (Fig. 1C). This indicates that the [alpha]2,6-sialic acid content is important for mimicking circulating TSH.
Regarding the fucose content, we observed rather poor agreement between 3/6Sial(-Fuc)-recTSH and serum TSH [slope, 0.703 (0.031); Fig. 4C]. In contrast, the 3/6Sial(+Fuc)-recTSH preparation (Fig. 4D) had a slope of 0.985 (0.044), indicating more similarity between this preparation and serum TSH.
The immunochemical behavior of 6Sial-recTSH without or with core fucosylation is presented in panels E and F, respectively, of Fig. 4. The 6Sial(-Fuc)-recTSH fraction was definitely the preparation most distant from serum TSH [slope, 0.496 (0.0630; Fig. 4E], whereas the presence of fucose in 6Sial(+Fuc)-recTSH produced somewhat better agreement with the serum pool [slope, 0.724 (0.063); Fig. 4F], but the agreement was not sufficient for that preparation to be a successful mimic of serum TSH. In addition, the variation in values was indicative of the influence of fucose in antibody recognition.
OVERALL EVALUATION OF THE REMODELED TSH PREPARATIONS
In this study, we purposely avoided any use of Reference Materials, which could have biased the quantitative epitope mapping. Rather, all of the remodeled and chromatographic fractions were compared on a molar basis, as described in the Materials and Methods.
The data for the various TSH preparations tested are summarized in Table 1. Mean values were calculated from at least 3 independent experiments for each comparison with recTSH, and with at least 2 independent experiments for comparison with serum TSH.
Correlation coefficients ([r.sup.2]) were >0.900 in 62.5% of the paired mappings, indicating satisfactory correlation with serum TSH, whereas for others, including pitTSH and resialylated preparations, the results were more divergent, as indicated by coefficients [less than or equal to]0.855. Slopes for the linear regression between each fraction (x) and the pooled sera (y) ranged from 0.496 for 6Sial(-Fuc)-recTSH to 2.124 for pitTSH, demonstrating up to a 4-fold difference in antibody recognition throughout the panel of assays. Interestingly, slope values ranged from 0.953 to 1.178 for 3 preparations varying in sialic acid content, suggesting that sialylated TSH glycoforms are definitely in close agreement with serum TSH. Among these preparations, fucosylated fractions displayed intercept values close to 0 compared with nonfucosylated preparations, indicating that internal glycosylation may play an additional role in the ability of assays to measure the widest spectrum of glycoforms. It thus appeared that remodeling a recTSH preparation may provide several good molecular mimics of circulating TSH for further harmonization of TSH tests.
[FIGURE 3 OMITTED]
[FIGURE 4 OMITTED]
This study aimed at establishing the feasibility of selecting potential candidates) for a new Reference Material for TSH immunoprocedures. A first recombinant IRP was established recently (48), but there has not been clear use of this material because measurements calibrated against the pitTSH 2nd IRP (80/558) showed fairly broad dispersion. To overcome this limitation, we produced several new recTSH preparations and determined which may best satisfy epitope similarity with serum samples. Our antibody panel targeted 3 antigenic clusters present in both Reference Materials, the pitTSH 2nd IRP (80/558) and the recTSH 1st IRP (94/674) (32, 47). From there, we designed a procedure to measure epitope expression as it may vary in circulating forms of TSH, independently of the routinely used calibrators.
TSH, like many other circulating glycoproteins, is known to exhibit large variations attributable to glycosylation under pathophysiologic conditions (3). As a result, discordantes in TSH measurements originate from the nonidentical epitope expression between serum samples and the calibrator (30, 31, 49, 50). In addition, epitope expression may be altered because TSH glycosylation changes during hypothyroidism. We thus wanted to define a procedure that can properly assess the changes in immunologic potency that occur during most common thyroid disorders, particularly hypothyroidism (11). We therefore produced several TSH preparations and compared them with TSH in sera from patients with thyroid disorders. We took advantage of an engineered TSH preparation produced in CHO cells because this cell line contains the enzymatic machinery to produce a complex serum-type glycosylation, except for [alpha]2,6-sialylation (47). This glycosidic linkage is of particular importance because we recently showed that epitope expression of both pituitary and recombinant TSH is under the influence of terminal sialylation (32).
Using TSH produced in CHO cells as starting material, we designed enzymatic procedures to remodel the sialic acid content in recTSH and fractionated the resulting preparations according to their core fucosylation to produce 7 well-defined glycoform subsets. We mapped all of these preparations by use of a panel of 23 immunoassays targeting 6 distinct antigenic determinants and subsequently compared all them against serum. We finally identified 3 potential candidates that displayed epitope expression comparable to TSH circulating in hypothyroid patients. At present, the next step will be to measure the frequency of the appearance of disease-related forms when primary or hypothalamic hypothyroidism develops, as well as other thyroid diseases. To this end, efforts are currently being made to adapt the differential screening used in this study to automated methods.
Most existing antibodies target 3 antigenic regions in the TSH molecule designated as I, II, and III, and our panel of assays divided them into 2 groups based on the different binding capacities. We previously showed that each cluster included at least 2 close epitopes (32). As a result, all determinants could be further mapped by use of 23 pairs of antibodies representing 6 distinct formats: I/II, I/III, II/I, II/III, III/I, and III/II. The III/II format gave the highest binding capacity because this combination of antibodies targeted all glycoforms independently of changes in TSH glycosylation, i.e., fucosylated as well as nonfucosylated (cluster III) and sialyaated as well as nonsialylated (cluster II) glycoforms. In contrast, the formats I/II, I/III, and la/Ib gave lower binding capacities; these formats all target cluster I, the main immunogenic region, which has been characterized as dependent on changes in glycosylation (32). Some antibodies thus displayed preference for some glycoforms and thereby induced discordantes among assays, particularly when these assays had been calibrated against the pitTSH standard. Our study identified the cause of differences in TSH values over 3 generations of assays. Very interestingly, it also indicated to us that there were no limitations in the use of some existing antibodies to improve the accuracy of TSH measurements.
Our findings demonstrate that the expression pattern of TSH circulating in patients with increased TSH concentrations did not match with all the tested preparations, particularly not with a highly purified pituitary preparation that was immunologically identical to the official reference preparation, pitTSH 2nd IRP. In contrast, recTSH preparations showed much better agreement with serum TSH. Remodeling of sialic acid content with [alpha]2,3-, [alpha]2,3/6-, or [alpha]2,6-linkages made it possible for us to explore the influence of 4 different terminal types of sialylation, despite the fact that the nature of TSH sialylation in serum cannot be determined. Indeed, we found that both the presence and the nature of sialic acid were of outmost importance for optimizing antibody recognition. The apparent role of fucosylation is to add a further level of complexity because the preference of some antibodies for nonfucosylated forms of TSH induced a broad divergence with serum samples, whereas fucosylated preparations showed closer similarities with serum TSH. This indicates that discordance in measurements can arise when an internal calibrator lacks fucose, such as TSH genetically engineered in yeast or insect cells. There is currently an ongoing active debate on defining the subnormal range of TSH by automated measurements; thus, new clinical investigations are needed. In this respect, our study indirectly supports a change toward new calibration of TSH measurements by providing new procedures and calibrators. To further explore this possibility, clinical studies will be shortly conducted within a working group of the IFCC Scientific Division.
We favor the view that a new calibrator is needed so that serum TSH can be measured with higher accuracy and possibly on a molar basis. Most of the formats that we tested were quite divergent when the calibrator was missing sialic acid, as in pitTSH, or a core fucose, as in nonfucosylated recTSH fractions. The current use of a pituitary IRP is likely to mask part, if not all, of the influence of sialic acid and may explain the disperse measurements encountered previously with the recombinant TSH in 1999 and still noted in most third-generation assays (43). In this respect, our strategy also suggests that recognition of disease-related forms of TSH may be further optimized by antibodies selection and construction of a Reference Material Procedure for TSH, which is not available at present. We hope that the best candidates) produced in this study will satisfy most clinical situations and shortly will be selected as new Reference Materials to meet the need of standardizing thyroid function testing.
This work was jointly supported by the Centre National de la Recherche Scientifique, the University of Provence, and the European Community through a grant on "In Vitro Diagnostic Procedures in Diagnosis and Monitoring of Thyroid Disease" (G6RD-CRT-2001-00587; Rudolf Lequin, coordinator). The Community is not responsible for any use that might be made of the data appearing within this report. The authors are solely responsible for the content of this study, which does not represent the opinion of the Community.
Received July 25, 2005; accepted November 7, 2005.
Previously published online at DOI: 10.1373/clinchem.2005.058172
(1.) Pierce JG, Parsons TF. Glycoprotein hormones: structure and function. Annu Rev Biochem 1981;50:465-95.
(2.) Ronin C, Papandreou MJ, Sergi S, Labbe-Jullie C, Medri G, Hoffmann T, et al. Glycosylation-dependent epitope mapping of human TSH (hTSH) isoforms. Int J Rad Appl Instrum B 1990;17: 651-6.
(3.) Szkudlinski MW, Fremont V, Ronin C, Weintraub BD. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol Rev 2002;82:473-502.
(4.) Szkudlinski MW, Thotakura NR, Weintraub BD. Subunit-specific functions of N-linked oligosaccharides in human thyrotropin: role of terminal residues of a- and R-subunit oligosaccharides in metabolic clearance and bioactivity. Proc Natl Acad Sci U S A 1995;92:9062-6.
(5.) Canonne C, Papandreou MJ, Medri G, Verrier B, Ronin C. Biological and immunochemical characterization of recombinant human thyrotrophin. Glycobiology 1995;5:473-81.
(6.) Cole ES, Lee K, Lauziere K, Kelton C, Chappel S, Weintraub B, et al. Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Biotechnology (NY) 1993;11:101424.
(7.) Grabenhorst E, Schlenke P, Pohl S, Nimtz M, Conradt HS. Genetic engineering of recombinant glycoproteins and the glycosylation pathway in mammalian host cells. Glycoconj J 1999;16:81-97.
(8.) Gerngross TU. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 2004; 22:1409-14.
(9.) Grossmann M, Wong R, Teh NG, Tropea JE, East-Palmer J, Weintraub BD, et al. Expression of biologically active human thyrotropin (hTSH) in a baculovirus system: effect of insect cell glycosylation on hTSH activity in vitro and in vivo. Endocrinology 1997;138:92-100.
(10.) Miura Y, Perkel VS, Papenberg KA, Johnson MJ, Magner JA. Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyro tropin in sera of euthyroid, primary, and central hypothyroid patients. J Clin Endocrinol Metab 1989;69:985-95.
(11.) Papandreou MJ, Persani L, Asteria C, Ronin C, Beck-Peccoz P. Variable carbohydrate structures of circulating thyrotropin as studied by lectin affinity chromatography in different clinical conditions. J Clin Endocrinol Metab 1993;77:393-8.
(12.) Trojan J, Theodoropoulou M, Usadel KH, Stalla GK, Schaaf L. Modulation of human thyrotropin oligosaccharide structures-enhanced proportion of sialylated and terminally galactosylated serum thyrotropin isoforms in subclinical and overt primary hypothyroidism. J Endocrinol 1998;158:359-65.
(13.) Persani L, Borgato S, Romoli R, Asteria C, Pizzocaro A, Beck-Peccoz P. Changes in the degree of sialylation of carbohydrate chains modify the biological properties of circulating thyrotropin isoforms in various physiological and pathological states. J Clin Endocrinol Metab 1998;83:2486-92.
(14.) Schaaf L, Trojan J, Helton TE, Usadel KH, Magner JA. Serum thyrotropin (TSH) heterogeneity in euthyroid subjects and patients with subclinical hypothyroidism: the core fucose content of TSH releasing hormone-released TSH is altered, but not the net charge of TSH. J Endocrinol 1995;144:561-71.
(15.) Fiete D, Srivastava V, Hindsgaul 0, Baenziger JU. A hepatic reticuloendothelial cell receptor specific for S04-4GaINAc [beta] 1,4GIcNAc [beta] 1,2Man [alpha] that mediates rapid clearance of lutropin. Cell 1991;67:1103-10.
(16.) Bianucci AM, Chiellini F. A 3D model for the human hepatic asialoglycoprotein receptor (ASGP-R). J Biomol Struct Dyn 2000; 18:435-51.
(17.) Joziasse DH, Lee RT, Lee YC, Biessen EA, Schiphorst WE, Koeleman CA, et al. a3-Galactosylated glycoproteins can bind to the hepatic asialoglycoprotein receptor. Eur J Biochem 2000;267: 6501-8.
(18.) Meier M, Bider MD, Malashkevich VN, Spiess M, Burkhard P. Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Biol 2000;300: 857-65.
(19.) Pricer WE Jr, Ashwell G. The binding of desialylated glycoproteins by plasma membranes of rat liver. J Biol Chem 1971;246:482533.
(20.) Pricer WE Jr, Hudgin RL, Ashwell G, Stockert RJ, Morell AG. A membrane receptor protein for asialoglycoproteins. Methods Enzymol 1974;34:688-91.
(21.) Townsend R, Stahl P. Isolation and characterization of a mannose/luacetylglucosamine/fucose-binding protein from rat liver. Biochem J 1981;194):209-14.
(22.) Magnusson S, Berg T. Endocytosis of ricin by rat liver cells in vivo and in vitro is mainly mediated by mannose receptors on sinusoidal endothelial cells. Biochem J 1993;291:749-55.
(23.) Smedsrod B, Einarsson M. Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver. Thromb Haemost 1990;63:60-6.
(24.) Lehrman MA, Haltiwanger RS, Hill RL. The binding of fucosecontaining glycoproteins by hepatic lectins. The binding specificity of the rat liver fucose lectin. J Biol Chem 1986;261:7426-32.
(25.) Shimada T, Higashi K, Umeda T, Sato T. Thyroid functions in patients with various chronic liver diseases. Endocrinol Jpn 1988; 35:357-69.
(26.) L'age M. Meinhold, Wenzel KW, Schleusener H. Relations between serum levels of TSH, TBG, T4, T3, rT3 and various histologically classified chronic liver diseases. J Endocrinol Invest 1980;3:379-83.
(27.) Agha F, Qureshi H, Khan RA. Serum thyroid hormone levels in liver cirrhosis. J Pak Med Assoc 1989;39:179-83.
(28.) Papandreou MJ, Sergi I, Benkirane M, Ronin C. Carbohydrate-dependent epitope mapping of human thyrotropin. Mol Cell Endocrinol 1990;73:15-26.
(29.) Sergi I, Papandreou MJ, Medri G, Canonne C, Verrier B, Ronin C. Immunoreactive and bioactive isoforms of human thyrotropin. Endocrinology 1991;128:3259-68.
(30.) Zerfaoui M, Ronin C. Glycosylation is the structural basis for changes in polymorphism and immunoreactivity of pituitary glycoprotein hormones. Eur J Clin Chem Clin Biochem 1996;34:74953.
(31.) Kashiwai T, Ichihara K, Endo Y, Tamaki H, Amino N, Miyai K. Immunological and biological characteristics of recombinant human thyrotropin. J Immunol Methods 1991;143:25-30.
(32.) Donadio S, Morelle W, Pascual A, Romi-Lebrun R, Michalski JC, Ronin C. Both core and terminal glycosylation alter epitope expression in thyrotropin and introduce discordantes in hormone measurements. Clin Chem Lab Med 2005;43:519-30.
(33.) Dayan CM. Interpretation of thyroid function tests. Lancet 2001; 357:619-24.
(34.) Wood WG, Waller D, Hantke U. An evaluation of six solid-phase thyrotropin (TSH) kits. J Clin Chem Clin Biochem 1985;23:46171.
(35.) Carayon P, Martino E, Bartalena L, Grasso L, Mammoli C, Costagliola S, et al. Clinical usefulness and limitations of serum thyrotropin measurement by 'ultrasensitive' methods. Comparisons of five kits. Horm Res 1987;26:105-17.
(36.) Chan BY, Swaminathan R. Analytical and clinical performance of six sensitive thyrotrophin kits. Pathology 1990;22:11-5.
(37.) Laurberg P. Persistent problems with the specificity of immunometric TSH assays. Thyroid 1993;3:279-83.
(38.) Spencer CA, Takeuchi M, Kazarosyan M, MacKenzie F, Beckett GJ, Wilkinson E. Interlaboratory/intermethod differences in functional sensitivity of immunometric assays of thyrotropin (TSH) and impact on variability of measurements of subnormal concentrations of TSH. Clin Chem 1995;41:367-74.
(39.) Wood WG, Bruns U, Eber 0, Langsteger W, Bounaud JY, Bounaud MP. Evaluation of the Abbott IMx ultrasensitive II hTSH immunometric assay in three European centres: a comparison with established commercial immunometric assays for thyrotropin. Eur J Clin Chem Clin Biochem 1996;34:151-8.
(40.) Rasmussen AK, Hilsted L, Perrild H, Christiansen E, Siersbaek-Nielsen K, Feldt-Rasmussen U. Discrepancies between thyrotropin (TSH) measurement by four sensitive immunometric assays. Clin Chim Acta 1997;259:117-28.
(41.) Price A, Burgin C, Catch I, Cruise M. Functional sensitivity and recovery of thyroid-stimulating hormone [Letter]. Clin Chem 2001; 47:2067.
(42.) Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf) 2003;58:138-40.
(43.) Rawlins ML, Roberts WL. Performance characteristics of six third-generation assays for thyroid-stimulating hormone. Clin Chem 2004;50:2338-44.
(44.) Muller MM. Implementation of reference systems in laboratory medicine. Clin Chem 2000;46:1907-9.
(45.) Lequin RM. Standardization: comparability and traceability of laboratory results. Clin Chem 2002;48:391-3.
(46.) Legaigneur P, Breton C, El Battari A, Guillemot JC, Auge C, Malissard M, et al. Exploring the acceptor substrate recognition of the human R-galactoside a 2,6-sialyltransferase. J Biol Chem 2001;276:21608-17.
(47.) Donadio S, Pascual A, Dugas M, Ronin C. Standardisation des immunodosages de la TSH: production de nouveaux calibrateurs et harmonisation des tests. Immunoanal Biol Spe 2006;in press.
(48.) Rafferty B, Gaines Das R. Comparison of pituitary and recombinant human thyroid-stimulating hormone (rhTSH) in a multicenter collaborative study: establishment of the first World Health Organization reference reagent for rhTSH. Clin Chem 1999;45:220715.
(49.) Thotakura NR, Desai RK, Bates LG, Cole ES, Pratt BM, Weintraub BD. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 1991;128:341-8.
(50.) Ribela MT, Bianco AC, Bartolini P. The use of recombinant human thyrotropin produced by Chinese hamster ovary cells for the preparation of immunoassay reagents. J Clin Endocrinol Metab 1996;81:249-56.
SANDRINE DONADIO,  AURELIE PASCUAL,  JOS H.H. THIJSSEN,  and CATHERINE RONIN *
 Laboratory of Neuroglycobiology, Universite de Provence, UMR 6149 et GDR 2590 CNRS/Universite de Provence, Marseille, France.
 Universitair Medish Centrum Utrecht, Utrecht, The Netherlands.
 Nonstandard abbreviations: TSH, thyroid-stimulating hormone (thyrotropin); pitTSH, pituitary thyroid-stimulating hormone; Ga1NAc, N-acetylgalactosamine; recTSH, recombinant thyroid-stimulating hormone; CHO, Chinese hamster ovary; NIBSC, National Institute for Biological Standards and Control; BSA, bovine serum albumin; IRP, International Reference Preparation; hST6Ga1 I, [beta]-galactoside [alpha]2,6-sialyltransierase; OSial-recTSH, desialylated recombinant thyroid-stimulating hormone; 3/6Sial-recTSH, oversialylated recombinant thyroid-stimulating hormone; and 6Sial-recTSH, resialylated recombinant thyroid-stimulating hormone.
* Address correspondence to this author at: Laboratoire de Neuroglycobiologie, Pole 3C Universite de Provence, Bafiment 9-Case B, UMR 6149 CNRS/Universite de Provence et GDR 2590, 3 Place Victor Hugo, 13331 Marseille Cedex 03, France. Fax 33-488-576-804; firstname.lastname@example.org.
Table 1. Summary of linear regression analysis for TSH preparations and serum samples from patients with thyroid disorders. (a) x y pitTSH recTSH pitTSH Serum TSH recTSH (3Sial-recTSH) Serum TSH recTSH recTSH (3Sial-recTSH) 0Sial-recTSH recTSH (3Sial-recTSH) 3/6Sial-recTSH recTSH (3Sial-recTSH) 6Sial-recTSH recTSH (3Sial-recTSH) 3/6Sial(-Fuc)-recTSH recTSH (3Sial-recTSH) 3/6Sial( Fuc)-recTSH recTSH (3Sial-recTSH) 6Sial(-Fuc)-recTSH recTSH (3Sial-recTSH) 6Sial( Fuc)-recTSH Serum TSH 3/6Sial-recTSH Serum TSH 3/6Sial(-Fuc)-recTSH Serum TSH 3/6Sial(+Fuc)-recTSH Serum TSH 6Sial-recTSH Serum TSH 6Sial(-Fuc)-recTSH Serum TSH 6Sial(+Fuc)-recTSH Serum TSH Slope Intercept, mIU/L 1.769 (0.055) 0.070 (0.217) 2.124 (0.001) 0.124 (0.003) 1.178 (0.056) -0.143 (0.115) recTSH 0.860 (0.057) 0.068 (0.068) 1.090 (0.084) -0.069 (0.018) 1.227 (0.029) -0.139 (0.145) 1.046 (0.090) 0.135 (0.075) 1.095 (0.075) -0.013 (0.098) 0.840 (0.017) 0.374 (0.010) 0.976 (0.024) 0.081 (0.137) 1.064 (0.057) -0.020 (0.090) Serum TSH 0.703 (0.031) -0.015 (0.061) 0.985 (0.044) -0.045 (0.019) 0.953 (0.033) -0.131 (0.015) 0.496 (0.063) 0.411 (0.183) 0.724 (0.172) 0.024 (0.010) [r.sup.2] 0.855 (0.114) 0.817 (0.087) 0.917 (0.028) recTSH 0.937 (0.057) 0.977 (0.012) 0.979 (0.014) 0.935 (0.021) 0.939 (0.030) 0.419 (0.192) 0.799 (0.128) 0.936 (0.001) 0.927 (0.021) Serum TSH 0.929 (0.057) 0.906 (0.030) 0.690 (0.111) 0.767 (0.016) (a) Values for the slope, intercept, and [r.sup.2] are the mean (SD).
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Other Areas of Clinical Chemistry|
|Author:||Donadio, Sandrine; Pascual, Aurelie; Thijssen, Jos H.H.; Ronin, Catherine|
|Date:||Feb 1, 2006|
|Previous Article:||Measurement of total vitamin [B.sub.12] and holotranscobalamin, singly and in combination, in screening for metabolic vitamin [B.sub.12] deficiency.|
|Next Article:||Performance evaluation and subsequent clinical experience with the Abbott automated architect STAT troponin-I assay.|